Clinical Trial NU VCC11CC01
- Randomized Placebo Controlled Double-Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
- Principal Investigator
- Surendra Basti
- Status: CLOSED
- Study Type: Therapeutic, Symptom Management
- Protocol No:.NU VCC11CC01
- The purpose of this study is to see how effective Restasis is in the prevention of ocular graft-versus-host disease (GVHD).
- Participants in this study have had a stem cell transplant from a donor (allogeneic transplant). People who have had an allogeneic transplant are at risk of getting chronic graft-versus-host disease (cGVHD). Dry eye is one of the symptoms of cGVHD of the eye. The study drug, called Restasis, is approved by the Food and Drug Administration (FDA) in the non-transplant population to help increase the production of tears. The use of Restasis in the transplant population is investigational, meaning non-FDA approved.
Some of the eligibility criteria include:
- Participant must be at least 18 years of age.
- Participant must not have a diagnosis of ocular GVHD at time of study enrollment.
- Participants in this study must have had a stem cell transplant from a donor.
- Description of Treatment
- Participants will receive either Restasis or placebo. This is a blinded and randomized study, which means each participant will be assigned by chance to either Restasis® or placebo, a substance with no active medicine. Neither participant, nor doctor, will know which group is the participant is in. Participants will place one drop of Restasis or placebo in each eye twice a day until the end of the study (1 year after transplant).
- Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
- Leukemia: Lymphoid leukemia
- Leukemia: Myeloid leukemia
- Lymphoma: Hodgkin's Disease
- Lymphoma: Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Bone Marrow Transplant: Lymphoid leukemia
- Bone Marrow Transplant: Myeloid leukemia
- Bone Marrow Transplant: Hodgkin's Disease
- Bone Marrow Transplant: Non-Hodgkin's Lymphoma
- Bone Marrow Transplant: Multiple Myeloma
last updated: 24-May-17 02:36 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.